Victoria N. Karetnikova

Victoria N. Karetnikova

Auto-generated profile, based on publicly available information

Victoria N. Karetnikova

Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
DBDaria Borodkina
Daria Borodkina
OAOlga Akbasheva
Olga Akbasheva
OBOlga Barbarash
Olga Barbarash
Determination of the impact of visceral obesity and epicardial adipose tissue thickness on stimulating growth factor levels during hospitalization for myocardial infarction is of potential importance for predicting outcomes and assessing the development of cardiofibrotic changes associated with maladaptive myocardial remodeling. In this study, we aimed to investigate the relationships between epicardial adipose tissue thickness, adipokine profiles, and the stimulating growth factor 2/interleukin-33 signaling system during hospitalization for myocardial infarction, and with the cardiac fibrosis extent 1-year post-MI in patients with visceral obesity. Eighty-eight patients with myocardial infarction were grouped based on their visceral obesity. Serum leptin, adiponectin, stimulating growth factor 2, and interleukin-33 levels were measured on days 1 and 12 and at 1 year. The epicardial adipose tissue widths and the cardiac fibrosis areas were measured on day 12 and at 1 year. Visceral obesity was associated with epicardial adipose tissue thickness increases, adipokine imbalances, elevated leptin levels, and lower adiponectin levels during early hospitalization, and cardiac fibrosis development. Patients without visceral obesity had higher interleukin-33 and stimulating growth factor 2 levels during early hospitalization and lower cardiac fibrosis rates. Epicardial adipose tissue thickness was positively associated with cardiac fibrosis prevalence and interleukin-33 levels and negatively associated with stimulating growth factor 2 levels. The cardiac fibrosis extent was negatively associated with interleukin-33 levels and positively associated with stimulating growth factor 2 levels. Increases in epicardial adipose tissue thickness are associated with cardiac fibrosis development 1-year post-myocardial infarction and are higher in patients with visceral obesity. The metabolic activity of the epicardial adipose tissue is associated with elevated interleukin-33 and reduced stimulating growth factor 2 levels.

9 July 2014 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
EBEkaterina Belik
Ekaterina Belik
VKVictoria Karetnikova
Victoria Karetnikova
OBOlga Barbarash
Olga Barbarash
Free fatty acids (FFA), oxidized low-density lipoprotein (LDL) and its antibodies, lipid profile markers, which are formed under oxidative stress, play an important role in atherosclerotic disease. Assess the levels of these markers in myocardial infarction patients depending on the extent of coronary artery disease (CAD). ST-elevation MI patients with hemodynamically significant stenoses of ≥75% in one, two, three, or more coronary arteries were examined. The patients were divided into three groups according to the severity of coronary lesions. Patients had a ≥75% stenotic lesion in one coronary artery (group 1, n = 135), two coronary arteries (group 2, n = 115), or three or more coronary arteries (group 3, n = 150). The control group comprised healthy subjects (n = 33). FFA levels on day 1 from MI onset were higher in groups 1, 2, and 3 compared with controls. On day 1 from MI onset, oxidized LDL levels were significantly higher in groups 2 and 3 than those in controls (both р = 0.001). Oxidized LDL levels were significantly higher in patients with multivessel CAD compared with those with single-vessel CAD on days 1 and 12. Antibody levels increased with the number of affected arteries. High levels FFA, oxidized LDL and its antibody, lipid profile markers, and parameters of the pro/antioxidant systems persist during the subacute phase of MI.

24 June 2020 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
VKV. N. Karetnikova
V. N. Karetnikova
Vasily KashtalapVasily Kashtalap
Vasily Kashtalap
TZT. N. Zvereva
T. N. Zvereva
AKAnastasia Kochergina
Anastasia Kochergina
The management of these patients requires healthcare professionals to have specific knowledge on the characteristics of the viral infection, its clinical signs and symptoms combined with cardiovascular diseases, as well as individual and collective prevention measures. The safety of healthcare professionals and favorable prognosis of patients are of the top priority for the modern healthcare system.The review discusses current challenges associated with the novel coronavirus disease COVID-19 and cardiovascular diseases. The results of few clinical trials and individual case reports have shown the presence of certain problems in treating patients with comorbidity and viral infection. The new data on the drug interactions are reported. Common patterns of typical cardiovascular diseases and COVID-19 are presented. The risk groups with the need for timely diagnosis and intensive cardiac care are identified to prevent adverse outcomes in patients with this comorbidity.

1 July 2016 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
EBEkaterina Belik
Ekaterina Belik
ASAleksandr Shilov
Aleksandr Shilov
Barbarash O, et al. Ann Lab Med. 2016 Jul;36(4):313-319. http://dx.doi.org/10.3343/alm.2016.36.4.313

8 May 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
MVM. I. Voyevoda
M. I. Voyevoda
GGG. R. Galstyan
G. R. Galstyan
MSMarina Shestakova
Marina Shestakova
SBSergey Boytsov
Sergey Boytsov
GCGalina Chumakova
Galina Chumakova
Предиабет как междисциплинарная проблема: определение, риски, подходы к диагностике и профилактике сахарного диабета 2 типа и сердечно-сосудистых осложнений

17 March 2016 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
EBEkaterina Belik
Ekaterina Belik
AKAlexander Kokov
Alexander Kokov
This study aimed to evaluate the markers of insulin resistance and adipokine status in patients with visceral obesity during hospitalization following myocardial infarction (MI) and assess the disturbances of carbohydrate metabolism present 1 year after MI onset. 94 male patients with MI were recruited. The exclusion criteria were as follows: age less than 50 or greater than 80 years, the presence of type 2 diabetes mellitus (T2DM), and a prior history of pronounced renal failure.Obesity types were defined according to body mass index (BMI), waist circumference (WC) and visceral adipose tissue (VAT) area. Glucose, insulin, adiponectin, leptin, and insulin resistance (IR) index were measured on days 1 and 12 after the onset of MI. New-onset type 2 diabetes was assessed 1 year after MI onset. According to computed tomography assessments of all study patients, 69 % of patients with MI suffered from visceral obesity. The VAT area was more closely associated with the risk of developing type 2 diabetes compared with the obesity parameters, BMI and WC. Patients with a VAT area greater than 130 cm2 had a 3.6-fold higher risk of developing type 2 diabetes. The presence of IR and hyperleptinemia increased the risk of developing diabetes in the post-MI period 3.5 and 3.7 times, respectively, in patients with visceral obesity compared with patients without visceral obesity. Visceral obesity is associated with IR, a 5.7-fold increase in leptin levels and a high risk of developing type 2 diabetes 1 year after MI onset.